Abstract P3-13-01: Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC)
Cancer Res (2013) 73 (24_Supplement): P3-13-01.
Currently there are no citedby results. Try again later.
